AiCuris 
Welcome,         Profile    Billing    Logout  
 1 Product   1 Disease  1 Product   12 Trials   812 News 
49 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Prevymis (letermovir) / Merck (MSD)
NCT05914675: Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

Not yet recruiting
4
21
NA
Letermovir
Institute of Hematology & Blood Diseases Hospital
The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
12/24
12/24
NCT05914701: Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT

Not yet recruiting
4
31
NA
Letermovir for secondary prophylaxis, secondary prophylaxis of CMV reactivation
Institute of Hematology & Blood Diseases Hospital
To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
12/24
12/24
NCT04904614: Letermovir Use in Heart Transplant Recipients

Completed
4
31
US
Letermovir
Tufts Medical Center, Merck Sharp & Dohme LLC
Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia
01/25
01/25
NCT05626530: Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

Recruiting
4
25
US
Letermovir, Active drug
Tufts Medical Center
Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia, Antiviral Toxicity
12/25
12/25
2020-002924-35: Traitement prénatal de l'infection congénitale à cytomégalovirus par le letermovir randomisé contre le valaciclovir Traitement prénatal de l'infection congénitale à cytomégalovirus par le letermovir randomisé contre le valaciclovir

Not yet recruiting
3
56
Europe
Valaciclovir Arrow, Prevymis, Tablet, Valaciclovir Arrow 500 mg, Prevymis
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS, ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS
Step 1: Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOPStep 2: Maternal daily administration of 240 or 480 milligrams of letermovir (1x240 mg-tablets) or (1x480 mg-tablets) (the dose will be choosen depending on the results obtained on step 1) up-until delivery or TOP Étape 1 : Administration maternelle d'un comprimé de Letermovir (240 mg ou 480 mg /jour) pendant 3 jours avant l’IMGÉtape 2 : Administration quotidienne par la mère de 240 ou 480 milligrammes de létermovir (1x240 mg) ou (1x480 mg) (la dose sera choisie en fonction des résultats obtenus à l'étape 1) jusqu'à l'accouchement ou IMG, Pregnant women with a fetus infected with cytomegaloviru.Test the efficacy of a new antiviral Letermovir on cytomegalovirus infection in the fetus versus the Valaciclovir already used in this context. Femmesenceintesavec fœtus infecté par le cytomégaloviruTester l’efficacitéd’unnouvel antiviralleLetermovirsurl’infection cytomégalovirus du fœtus versus le Valaciclovir déjà utilisé dans ce contexte., Diseases [C] - Virus Diseases [C02]
 
 
NCT06341686: Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

Not yet recruiting
3
100
NA
Letermovir 480 MG, Ganciclovir
Hospital do Rim e Hipertensão
CMV Infection
03/25
05/25
MK-8228-045, NCT05763823: A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients

Completed
3
120
RoW
Letermovir, MK-8228
Merck Sharp & Dohme LLC
Cytomegalovirus Infection
04/24
04/24
NCT06407232: Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Recruiting
3
90
US
Letermovir, Prevymis
University of Wisconsin, Madison, Merck Sharp & Dohme LLC
Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant
09/26
09/26
LUCY-1, NCT06334497: Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections

Recruiting
3
80
Europe
Letermovir, Valganciclovir, Letermovir placebo
Assistance Publique - Hôpitaux de Paris
Cytomegalovirus Infection
09/27
11/27
NCT06001320: De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

Recruiting
3
60
US
Letermovir 480 mg once daily, Historical/Control
Virginia Commonwealth University, Merck Sharp & Dohme LLC
Kidney Transplant; Complications, CMV
09/25
09/26
NCT05711667: A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Active, not recruiting
3
143
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis
Children's Oncology Group
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
06/28
06/28
CYMEVAL3-step2, NCT05446571: Prenatal Treatment of Congenital Cytomegalovirus Infection with Letermovir Versus Valaciclovir

Recruiting
3
46
NA
Letermovir, Valacyclovir
Assistance Publique - Hôpitaux de Paris
Pregnant Women, CMV Infected Fetuses
08/29
08/29
2022-001514-18: Cytomegalovirus Prophylaxis with Letermovir in Heart Transplant Recipients: A Non-randomized Cohort Pilot Study

Not yet recruiting
2
90
Europe
Prevymis, Film-coated tablet, Prevymis
University Medical Center Ljubljana, MSD
The focus of investigation in the proposed study protocol is the rates of Cytomegalovirus viremia and/or disease in patients after heart transplantation undergoing novel CMV prophylaxis protocol using letermovir., CMV infection is the most prevalent infection after heart transplantation (HTX), occurring in up to 40-60% of the recipients. It most frequently occurs within the first 6 months after transplantation.
 
 
MK-8228-030, NCT03940586 / 2018-001326-25: Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)

Completed
2
65
Europe, Japan, US, RoW
Letermovir oral granules, MK-8228, AIC246, AIC001, Letermovir tablet, Letermovir intravenous
Merck Sharp & Dohme LLC
Cytomegalovirus (CMV) Infection
01/23
08/23
NCT04312841: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Completed
2
6
US
Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis
Ohio State University Comprehensive Cancer Center, Merck Sharp & Dohme LLC
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia
11/23
04/24
NCT06453460: Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla

Recruiting
2
50
US
Letermovir, CMV T Cell Immunity Panel (CMV-TCIP), CMV DNA PCR
University of California, Irvine, Eurofins Viracor
CMV, Allogeneic Stem Cell Transplantation
06/28
06/29
NCT04017962: A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Active, not recruiting
2
102
US
Letermovir Pill, LTV, blood draw
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
CMV, CMV Infection, Hematopoietic Cell Transplant
07/25
07/25
NCT05041426: Letermovir for CMV Prevention After Lung Transplantation

Active, not recruiting
2
16
US
Letermovir, Prevymis, Valganciclovir
Fernanda P Silveira, MD, MS, Merck Sharp & Dohme LLC
Lung Transplant, CMV
07/25
07/25
NCT06021210: Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

Recruiting
2
80
RoW
Letermovir Pill, Letermovir Tablets
The First Affiliated Hospital of Soochow University
CMV Infection, Hematopoietic Stem Cell Transplantation
07/24
09/25
PROACTIV, NCT06626555: Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection

Not yet recruiting
2
36
NA
Letermovir
University College, London, Royal Free Hospital NHS Foundation Trust
HIV
03/26
03/26
NCT06575374: Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell

Recruiting
2
36
US
Letermovir
M.D. Anderson Cancer Center
Cell Therapy
08/26
08/27
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

Terminated
2
44
US
Letermovir Oral Tablet, Prevymis
National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC
HIV Infections, Cytomegalovirus, CMV
11/23
11/23
NCT04060277: Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

Active, not recruiting
2
7
US
Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA Triplex Vaccine, Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Placebo Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
06/23
04/30
NCT05969743: Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease

Not yet recruiting
2
42
NA
Letermovir
Rabin Medical Center
Graft-versus-host-disease, CMV
04/25
07/25
OPTIMUS-EL, NCT06920251: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy

Not yet recruiting
2
40
RoW
Letermovir, Elranatamab
Seoul National University Hospital
Relapsed Refractory Multiple Myeloma (RRMM)
12/27
12/28
CYPHER-TXPilot, NCT05432778: Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients

Recruiting
2
90
Europe
Letermovir Pill
University Medical Centre Ljubljana
CMV Viremia
08/25
08/26
NCT06066957: Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Recruiting
2
80
US
Letermovir 480 MG [Prevymis]
University of Pennsylvania, Merck Sharp & Dohme LLC
Cytomegalovirus Infections, Transplant-Related Disorder
08/26
08/26
LETERCOR, NCT06057194: Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

Not yet recruiting
2
90
Europe
Letermovir 240 mg Oral Tablet
Maimónides Biomedical Research Institute of Córdoba, MERCK SHARP & DOHME DE ESPAÑA S.A.
Infections, Cytomegalovirus
04/27
04/27
NCT06118515: A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Recruiting
1
12
US
Letermovir
National Institute of Allergy and Infectious Diseases (NIAID)
Congenital Cytomegalovirus Infection
08/25
08/25
NCT07020533: A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Not yet recruiting
1
46
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation, Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical, Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA Triplex Vaccine, Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Myeloablative Conditioning, Myeloablation, Myeloablative, Myeloablative Cytoreduction, Pheresis, Apheresed, Apheresis, Blood Component Removal, Collection, Apheresis/Leukapheresis, Hemapheresis, Recombinant Granulocyte Colony-Stimulating Factor, Recombinant Colony-Stimulating Factor 3, rhG-CSF
City of Hope Medical Center, National Cancer Institute (NCI)
Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
06/27
06/27
NCT06306989: Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT

Recruiting
N/A
150
RoW
Letermovir
Cao Weijie
Letemovir for the Prevention of CMV Infection After Allo-HSCT
09/24
12/25
CMVbreak, NCT06339892: HCMV Breakthrough Infections During Letermovir Prophylaxis

Recruiting
N/A
140
Europe
Determination of HCMV DNA in plasma after DNAse digestion., Determination of HCMV DNA in blood or plasma.
Fondazione IRCCS Policlinico San Matteo di Pavia, Ministero della Salute, Italy
Cytomegalovirus Infections, Cytomegalovirus Viremia, Hematopoietic Stem Cell Transplantation
06/25
03/26
NCT06211543: Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers

Not yet recruiting
N/A
80
NA
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
CMV
09/25
03/26
NCT06441669: Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Recruiting
N/A
60
RoW
Letermovir
Anhui Provincial Hospital
Cytomegalovirus Infection Reactivation
05/26
05/26
NCT06449586: CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

Recruiting
N/A
250
RoW
Letermovir
Ruijin Hospital
Hematologic Malignancy
06/25
06/26
NCT06524973: Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers

Recruiting
N/A
136
US
Telemedicine, Counseling, Best Practice, Questionnaire Administration, Inrweview
City of Hope Medical Center
Metastatic Pancreatic Adenocarcinoma
05/27
05/27
NCT06639854: The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Recruiting
N/A
105
US
Hematopoietic Cell Transplant, Letermovir
M.D. Anderson Cancer Center
Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant
12/26
12/26
NCT05656599: Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies

Enrolling by invitation
N/A
120
RoW
Letermovir
Peking University People's Hospital
CMV Infection, Hematopoietic Stem Cell Transplantation
12/24
12/25
NCT05789615: Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China

Completed
N/A
200
RoW
Letermovir
The First Affiliated Hospital of Soochow University, Merck Sharp & Dohme LLC
CMV Infection, Hematopoietic Stem Cell Transplantation
01/25
01/25
NCT06812598: Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

Recruiting
N/A
330
RoW
Letermovir (0-24w）, Letermovir (0-14w）
The First Affiliated Hospital of Soochow University
Cytomegalovirus Infections, CMV
12/25
12/25
INMUNOEND, NCT06814301: Impact of CMV-Specific Immune Reconstitution At the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients

Not yet recruiting
N/A
123
Europe
Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
Maimónides Biomedical Research Institute of Córdoba
Cytomegalovirus Cell Mediated Immunity, Stem Cell Transplantation, Hematopoietic
06/27
09/27
ChiCTR2500100795: Evaluation of the use of Ganciclovir and Letermovir in special patients and optimization of clinical dosing regimens

Completed
N/A
150
 
None
the First Affiliated Hospital of Xian Jiaotong University; the First Affiliated Hospital of Xian Jiaotong University, none
CMV infection
 
 
NCT05362916: Letermovir in ART-treated HIV-infected Persons

Recruiting
N/A
60
Canada
Letermovir, PREVYMIS
Jean-Pierre Routy
People Living With HIV
04/25
12/25
ChiCTR2500100895: Harmacokinetics of Letermovir in Pediatric Recipients Following Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Not yet recruiting
N/A
10
 
Letermovir
Blood Disease Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences); Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Self-selected project (self-funded)
allogeneic hematopoietic stem cell transplantation
 
 
ChiCTR2500096057: Dosing optimization of letermovir in allogeneic hematopoietic stem cell transplantation by population pharmacokinetic and pharmacodynamic study

Not yet recruiting
N/A
30
 
The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, Optional topics
Allogeneic hematopoietic stem cell transplantation recipients
 
 
AIC649 / AiCuris
2021-000167-69: Novel AIC649 in otherwise healthy patients with asymptomatic or mildly symptomatic SARS-CoV-2 Infection

Not yet recruiting
1/2
60
Europe
inactivated Parapoxvirus ovis (iPPVO), AIC649, Lyophilisate for solution for injection
AiCuris Anti-Infective Cures AG, AiCuris Anti-Infective Cures AG
asymptomatic or mildly symptomatic SARS-CoV-2 infection, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
pritelivir (AIC316) / AiCuris
PRIOH-1, NCT03073967 / 2020-004940-27: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Recruiting
3
153
Europe, Canada, US, RoW
Pritelivir, Investigator's choice, Foscarnet or Cidofovir or Imiquimod
AiCuris Anti-infective Cures AG, Medpace, Inc.
HSV Infection
07/25
11/25
NCT05671029: Thorough QT/QTc of Pritelivir in Healthy Subjects

Completed
1
64
Europe
Pritelivir and moxifloxacin placebo, Pritelivir placebo, moxifloxacin and moxifloxacin placebo, Pritelivir placebo, moxifloxacin placebo and moxifloxacin
AiCuris Anti-infective Cures AG
Healthy Subjects
05/23
05/23
NCT05844436: Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2

Available
N/A
NA
Pritelivir
AiCuris Anti-infective Cures AG, Impatients N.V. trading as myTomorrows
HSV
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Prevymis (letermovir) / Merck (MSD)
NCT05914675: Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

Not yet recruiting
4
21
NA
Letermovir
Institute of Hematology & Blood Diseases Hospital
The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
12/24
12/24
NCT05914701: Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT

Not yet recruiting
4
31
NA
Letermovir for secondary prophylaxis, secondary prophylaxis of CMV reactivation
Institute of Hematology & Blood Diseases Hospital
To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
12/24
12/24
NCT04904614: Letermovir Use in Heart Transplant Recipients

Completed
4
31
US
Letermovir
Tufts Medical Center, Merck Sharp & Dohme LLC
Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia
01/25
01/25
NCT05626530: Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

Recruiting
4
25
US
Letermovir, Active drug
Tufts Medical Center
Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia, Antiviral Toxicity
12/25
12/25
2020-002924-35: Traitement prénatal de l'infection congénitale à cytomégalovirus par le letermovir randomisé contre le valaciclovir Traitement prénatal de l'infection congénitale à cytomégalovirus par le letermovir randomisé contre le valaciclovir

Not yet recruiting
3
56
Europe
Valaciclovir Arrow, Prevymis, Tablet, Valaciclovir Arrow 500 mg, Prevymis
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS, ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS
Step 1: Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOPStep 2: Maternal daily administration of 240 or 480 milligrams of letermovir (1x240 mg-tablets) or (1x480 mg-tablets) (the dose will be choosen depending on the results obtained on step 1) up-until delivery or TOP Étape 1 : Administration maternelle d'un comprimé de Letermovir (240 mg ou 480 mg /jour) pendant 3 jours avant l’IMGÉtape 2 : Administration quotidienne par la mère de 240 ou 480 milligrammes de létermovir (1x240 mg) ou (1x480 mg) (la dose sera choisie en fonction des résultats obtenus à l'étape 1) jusqu'à l'accouchement ou IMG, Pregnant women with a fetus infected with cytomegaloviru.Test the efficacy of a new antiviral Letermovir on cytomegalovirus infection in the fetus versus the Valaciclovir already used in this context. Femmesenceintesavec fœtus infecté par le cytomégaloviruTester l’efficacitéd’unnouvel antiviralleLetermovirsurl’infection cytomégalovirus du fœtus versus le Valaciclovir déjà utilisé dans ce contexte., Diseases [C] - Virus Diseases [C02]
 
 
NCT06341686: Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

Not yet recruiting
3
100
NA
Letermovir 480 MG, Ganciclovir
Hospital do Rim e Hipertensão
CMV Infection
03/25
05/25
MK-8228-045, NCT05763823: A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients

Completed
3
120
RoW
Letermovir, MK-8228
Merck Sharp & Dohme LLC
Cytomegalovirus Infection
04/24
04/24
NCT06407232: Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Recruiting
3
90
US
Letermovir, Prevymis
University of Wisconsin, Madison, Merck Sharp & Dohme LLC
Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant
09/26
09/26
LUCY-1, NCT06334497: Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections

Recruiting
3
80
Europe
Letermovir, Valganciclovir, Letermovir placebo
Assistance Publique - Hôpitaux de Paris
Cytomegalovirus Infection
09/27
11/27
NCT06001320: De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

Recruiting
3
60
US
Letermovir 480 mg once daily, Historical/Control
Virginia Commonwealth University, Merck Sharp & Dohme LLC
Kidney Transplant; Complications, CMV
09/25
09/26
NCT05711667: A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Active, not recruiting
3
143
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis
Children's Oncology Group
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
06/28
06/28
CYMEVAL3-step2, NCT05446571: Prenatal Treatment of Congenital Cytomegalovirus Infection with Letermovir Versus Valaciclovir

Recruiting
3
46
NA
Letermovir, Valacyclovir
Assistance Publique - Hôpitaux de Paris
Pregnant Women, CMV Infected Fetuses
08/29
08/29
2022-001514-18: Cytomegalovirus Prophylaxis with Letermovir in Heart Transplant Recipients: A Non-randomized Cohort Pilot Study

Not yet recruiting
2
90
Europe
Prevymis, Film-coated tablet, Prevymis
University Medical Center Ljubljana, MSD
The focus of investigation in the proposed study protocol is the rates of Cytomegalovirus viremia and/or disease in patients after heart transplantation undergoing novel CMV prophylaxis protocol using letermovir., CMV infection is the most prevalent infection after heart transplantation (HTX), occurring in up to 40-60% of the recipients. It most frequently occurs within the first 6 months after transplantation.
 
 
MK-8228-030, NCT03940586 / 2018-001326-25: Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)

Completed
2
65
Europe, Japan, US, RoW
Letermovir oral granules, MK-8228, AIC246, AIC001, Letermovir tablet, Letermovir intravenous
Merck Sharp & Dohme LLC
Cytomegalovirus (CMV) Infection
01/23
08/23
NCT04312841: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Completed
2
6
US
Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis
Ohio State University Comprehensive Cancer Center, Merck Sharp & Dohme LLC
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia
11/23
04/24
NCT06453460: Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla

Recruiting
2
50
US
Letermovir, CMV T Cell Immunity Panel (CMV-TCIP), CMV DNA PCR
University of California, Irvine, Eurofins Viracor
CMV, Allogeneic Stem Cell Transplantation
06/28
06/29
NCT04017962: A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Active, not recruiting
2
102
US
Letermovir Pill, LTV, blood draw
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
CMV, CMV Infection, Hematopoietic Cell Transplant
07/25
07/25
NCT05041426: Letermovir for CMV Prevention After Lung Transplantation

Active, not recruiting
2
16
US
Letermovir, Prevymis, Valganciclovir
Fernanda P Silveira, MD, MS, Merck Sharp & Dohme LLC
Lung Transplant, CMV
07/25
07/25
NCT06021210: Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

Recruiting
2
80
RoW
Letermovir Pill, Letermovir Tablets
The First Affiliated Hospital of Soochow University
CMV Infection, Hematopoietic Stem Cell Transplantation
07/24
09/25
PROACTIV, NCT06626555: Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection

Not yet recruiting
2
36
NA
Letermovir
University College, London, Royal Free Hospital NHS Foundation Trust
HIV
03/26
03/26
NCT06575374: Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell

Recruiting
2
36
US
Letermovir
M.D. Anderson Cancer Center
Cell Therapy
08/26
08/27
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

Terminated
2
44
US
Letermovir Oral Tablet, Prevymis
National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC
HIV Infections, Cytomegalovirus, CMV
11/23
11/23
NCT04060277: Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

Active, not recruiting
2
7
US
Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA Triplex Vaccine, Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Placebo Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
06/23
04/30
NCT05969743: Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease

Not yet recruiting
2
42
NA
Letermovir
Rabin Medical Center
Graft-versus-host-disease, CMV
04/25
07/25
OPTIMUS-EL, NCT06920251: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy

Not yet recruiting
2
40
RoW
Letermovir, Elranatamab
Seoul National University Hospital
Relapsed Refractory Multiple Myeloma (RRMM)
12/27
12/28
CYPHER-TXPilot, NCT05432778: Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients

Recruiting
2
90
Europe
Letermovir Pill
University Medical Centre Ljubljana
CMV Viremia
08/25
08/26
NCT06066957: Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Recruiting
2
80
US
Letermovir 480 MG [Prevymis]
University of Pennsylvania, Merck Sharp & Dohme LLC
Cytomegalovirus Infections, Transplant-Related Disorder
08/26
08/26
LETERCOR, NCT06057194: Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

Not yet recruiting
2
90
Europe
Letermovir 240 mg Oral Tablet
Maimónides Biomedical Research Institute of Córdoba, MERCK SHARP & DOHME DE ESPAÑA S.A.
Infections, Cytomegalovirus
04/27
04/27
NCT06118515: A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Recruiting
1
12
US
Letermovir
National Institute of Allergy and Infectious Diseases (NIAID)
Congenital Cytomegalovirus Infection
08/25
08/25
NCT07020533: A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Not yet recruiting
1
46
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation, Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical, Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA Triplex Vaccine, Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Myeloablative Conditioning, Myeloablation, Myeloablative, Myeloablative Cytoreduction, Pheresis, Apheresed, Apheresis, Blood Component Removal, Collection, Apheresis/Leukapheresis, Hemapheresis, Recombinant Granulocyte Colony-Stimulating Factor, Recombinant Colony-Stimulating Factor 3, rhG-CSF
City of Hope Medical Center, National Cancer Institute (NCI)
Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
06/27
06/27
NCT06306989: Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT

Recruiting
N/A
150
RoW
Letermovir
Cao Weijie
Letemovir for the Prevention of CMV Infection After Allo-HSCT
09/24
12/25
CMVbreak, NCT06339892: HCMV Breakthrough Infections During Letermovir Prophylaxis

Recruiting
N/A
140
Europe
Determination of HCMV DNA in plasma after DNAse digestion., Determination of HCMV DNA in blood or plasma.
Fondazione IRCCS Policlinico San Matteo di Pavia, Ministero della Salute, Italy
Cytomegalovirus Infections, Cytomegalovirus Viremia, Hematopoietic Stem Cell Transplantation
06/25
03/26
NCT06211543: Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers

Not yet recruiting
N/A
80
NA
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
CMV
09/25
03/26
NCT06441669: Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Recruiting
N/A
60
RoW
Letermovir
Anhui Provincial Hospital
Cytomegalovirus Infection Reactivation
05/26
05/26
NCT06449586: CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

Recruiting
N/A
250
RoW
Letermovir
Ruijin Hospital
Hematologic Malignancy
06/25
06/26
NCT06524973: Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers

Recruiting
N/A
136
US
Telemedicine, Counseling, Best Practice, Questionnaire Administration, Inrweview
City of Hope Medical Center
Metastatic Pancreatic Adenocarcinoma
05/27
05/27
NCT06639854: The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Recruiting
N/A
105
US
Hematopoietic Cell Transplant, Letermovir
M.D. Anderson Cancer Center
Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant
12/26
12/26
NCT05656599: Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies

Enrolling by invitation
N/A
120
RoW
Letermovir
Peking University People's Hospital
CMV Infection, Hematopoietic Stem Cell Transplantation
12/24
12/25
NCT05789615: Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China

Completed
N/A
200
RoW
Letermovir
The First Affiliated Hospital of Soochow University, Merck Sharp & Dohme LLC
CMV Infection, Hematopoietic Stem Cell Transplantation
01/25
01/25
NCT06812598: Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

Recruiting
N/A
330
RoW
Letermovir (0-24w）, Letermovir (0-14w）
The First Affiliated Hospital of Soochow University
Cytomegalovirus Infections, CMV
12/25
12/25
INMUNOEND, NCT06814301: Impact of CMV-Specific Immune Reconstitution At the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients

Not yet recruiting
N/A
123
Europe
Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
Maimónides Biomedical Research Institute of Córdoba
Cytomegalovirus Cell Mediated Immunity, Stem Cell Transplantation, Hematopoietic
06/27
09/27
ChiCTR2500100795: Evaluation of the use of Ganciclovir and Letermovir in special patients and optimization of clinical dosing regimens

Completed
N/A
150
 
None
the First Affiliated Hospital of Xian Jiaotong University; the First Affiliated Hospital of Xian Jiaotong University, none
CMV infection
 
 
NCT05362916: Letermovir in ART-treated HIV-infected Persons

Recruiting
N/A
60
Canada
Letermovir, PREVYMIS
Jean-Pierre Routy
People Living With HIV
04/25
12/25
ChiCTR2500100895: Harmacokinetics of Letermovir in Pediatric Recipients Following Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Not yet recruiting
N/A
10
 
Letermovir
Blood Disease Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences); Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Self-selected project (self-funded)
allogeneic hematopoietic stem cell transplantation
 
 
ChiCTR2500096057: Dosing optimization of letermovir in allogeneic hematopoietic stem cell transplantation by population pharmacokinetic and pharmacodynamic study

Not yet recruiting
N/A
30
 
The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, Optional topics
Allogeneic hematopoietic stem cell transplantation recipients
 
 
AIC649 / AiCuris
2021-000167-69: Novel AIC649 in otherwise healthy patients with asymptomatic or mildly symptomatic SARS-CoV-2 Infection

Not yet recruiting
1/2
60
Europe
inactivated Parapoxvirus ovis (iPPVO), AIC649, Lyophilisate for solution for injection
AiCuris Anti-Infective Cures AG, AiCuris Anti-Infective Cures AG
asymptomatic or mildly symptomatic SARS-CoV-2 infection, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
pritelivir (AIC316) / AiCuris
PRIOH-1, NCT03073967 / 2020-004940-27: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Recruiting
3
153
Europe, Canada, US, RoW
Pritelivir, Investigator's choice, Foscarnet or Cidofovir or Imiquimod
AiCuris Anti-infective Cures AG, Medpace, Inc.
HSV Infection
07/25
11/25
NCT05671029: Thorough QT/QTc of Pritelivir in Healthy Subjects

Completed
1
64
Europe
Pritelivir and moxifloxacin placebo, Pritelivir placebo, moxifloxacin and moxifloxacin placebo, Pritelivir placebo, moxifloxacin placebo and moxifloxacin
AiCuris Anti-infective Cures AG
Healthy Subjects
05/23
05/23
NCT05844436: Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2

Available
N/A
NA
Pritelivir
AiCuris Anti-infective Cures AG, Impatients N.V. trading as myTomorrows
HSV
 
 

Download Options